Nunzia Pharmaceutical Company

NUNZ

US67097W1027

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 08:10:00 2023-12-01 pm EST			5-day change	1st Jan Change
0.003 ^USD	-.--%		-.--%	-.--%

2022	Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

October 03, 2022 at 08:01 am EDT

Nunzia Pharmaceutical Company reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 0.0201 million compared to USD 0.006629 million a year ago.
For the six months, net loss was USD 18.74 million compared to USD 0.022277 million a year ago. Basic loss per share from continuing operations was USD 0.04.

Latest news about Nunzia Pharmaceutical Company

Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-10-03	CI
Nunzia Pharmaceutical Company Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-15	CI
Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	22-04-14	CI
Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	22-03-28	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	21-09-16	CI
Nunzia Pharmaceutical Corporation Announces Offering of Patented Blood Warmer Through Medical Supply Division	21-08-16	CI
Nunzia Pharmaceutical Corporation Signs A Licensing Agreement with Michael Mitsunaga	21-08-06	CI
Global WholeHealth Partners Corporation acquired distribution and selling rights of Moderna Vaccine of Nunzia Pharmaceutical Corporation.	21-06-24	CI
Global Wholehealth Partners Corporation Partners with Nunzia Pharmaceutical Inc. to Distribute and Sell the Pfizer-BioNTech COVID-19 Vaccine	21-06-16	CI
Global Wholehealth Partners Corporation Grants the Rights from Nunzia Pharmaceutical Inc. to Distribute and Sell the Johnson & Johnson Covid-19 Vaccine	21-06-10	CI
Global Wholehealth Partners Corp. Partners with Nunzia Pharmaceutical Inc., Opening New Avenues of Revenue and Products for Global	21-04-22	CI
Global Wholehealth Partners Corporation Enters into Mutual Sales and Marketing Agreement with Nunzia Pharmaceutical Inc	21-04-19	CI
Global WholeHealth Partners Corp Receives from Nunzia Pharmaceutical the Full Right as Distributor of Nunzia to Sell the ADZ 1222 Covid 19 Vaccine by Thameen Healthcare Trading LLC	21-03-08	CI
Nunzia Pharmaceutical Corporation Launches New Version of its Already Acclaimed NUNZIA Nutraceutical	20-04-16	CI
Nunzia Pharmaceutical Corporation Announces Availability of Nunzia Nutraceutical to Market	20-01-31	CI
Arizona Gold and Onyx Mining Company will Change its Name to Nunzia Pharmaceutical Corporation	19-12-04	CI
Nunzia Pharmaceutical Corporation will Change its Ticker to VGCP.D from VGCP	19-12-04	CI
Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-12-02	CI

Chart Nunzia Pharmaceutical Company

Duration

Period

More charts

Company Profile

Nunzia Pharmaceutical Corporation is a pharmaceutical company. The Company focuses on development and delivery of pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum of Disorders (ASDs) and related conditions, such as Fragile X syndrome, as well as common anxiety-based disorders. The Company has developed NUNZIA, which is a combination of 16 vitamins, minerals and herbs which directly focuses and targets the hippocampus area of the brain, where all anxiety-based disorders originate.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NUNZIA PHARMACEUTICAL COMPANY	-.--%	1.3M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals